Inclusion Body Myositis Associated With ‘Unique’ Comorbidities
Early recognition of comorbidities in inclusion body myositis can avert some of the potential...
Read More
Author: Rebecca Shover
AACR Virtual Meeting Platform
All sessions held in the Convention Center will be live-streamed to the virtual meeting platform....
Read More
AACR 5K For Research
Date/Time: Saturday, April 15, 2023; 7:30-10:30 a.m. ET Start/Finish: Orange County Convention...
Read More
AACR Schedule
FRIDAY, APRIL 14 12:00 p.m. Registration Opens 3:00 p.m.-4:30 p.m. Educational Sessions and...
Read More
Addressing Issues With EHRs
Electronic health records (EHRs) can be of great help to physicians, but their implementation is...
Read More
Is There an Ideal Time to Sell a Medical Practice?
There are many elements for physicians to consider when they ponder selling their medical...
Read More
How AI Applications Will Transform Healthcare
Natural language processing (NLP), the ability for computers and humans to communicate in a more...
Read More
Protect Yourself by Understanding Medical Malpractice Insurance
No matter how adept a physician is in their field, one key element to achieving and maintaining a...
Read More
Oral Immunotherapy Desensitizes Non-Milk Food Allergies in Adults
Although food allergies are a common pediatric concern, there are many adults who live with them...
Read More
Blockade of the IL-22 Receptor: Novel Treatment Approach in AD
IL-22 might be a novel target in the therapy of moderate-to-severe atopic dermatitis (AD). In a...
Read More
Biomarkers Assessments May Be Useful to Identify Treatment Response for CSU
Certain biomarkers in patients with chronic spontaneous urticaria (CSU) may predict the treatment...
Read More
Novel Potent Oral Medication for Psoriasis Proves Efficacious
A novel tyrosine kinase 2 (TYK2) inhibitor showed remarkable efficacy as a treatment for psoriasis...
Read More
Risankizumab: Valuable Treatment Option for IL-17 Inhibitor Non-Responders
Results of the AIMM study show that switching patients that show suboptimal response on an IL-17...
Read More
Topical Roflumilast Offers Early Itch Reduction in Atopic Dermatitis
For pediatric and adult patients with mild-to-moderate AD, roflumilast cream demonstrated a...
Read More
Deuruxolitinib Shows Promising Results in Alopecia Areata
Oral deuruxolitinib revealed significantly higher rates of hair re-growth than placebo in patients...
Read More
Bimekizumab: The New Rising Star for HS Therapy?
Within the BE HEARD trial, bimekizumab treatment resulted in significant benefits in the treatment...
Read More
Repigmentation Persists After Treatment Withdrawal from Topical Ruxolitinib
Following the success of a nearly complete re-pigmentation status in vitiligo on ruxolitinib...
Read More